Heart Tronics Inc (HRTT)

[TechKim]

Signalife, Inc. Unveils Fidelity 300 at ACC - March 24-27
Tuesday March 20, 9:37 am ET
http://biz.yahoo.com/prnews/070320/nytu085.html?.v=91

GREENVILLE, S.C., March 20 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) Signalife, Inc. announced on March 25 through March 27, at the American College of Cardiology 56th Annual Scientific Session in New Orleans, Louisiana, Signalife will unveil its new Fidelity 300 heart monitor. The Fidelity 300 provides superior long-term clinical quality monitoring capabilities from a device housing in a light and portable enclosure.


To demonstrate the efficacy of the Signalife technology, world-class athlete and Super Bowl winner Willie Gault -- from the 1985 Super Bowl Champion Chicago Bears -- will wear the Fidelity 100 and 300 devices while running on a treadmill at world class speeds. The device will garner a clinical quality ECG signal on a wide screen monitor for easy viewing. The demonstration will take place twice daily on Sunday and Monday at the company's booth #2875.

The Fidelity 300, built on the basis of the same award winning technologies as the Fidelity 100 which is currently in use, will be used for long term ECG recordings in clinical studies that are expected to start this summer and shall be announced by the Company soon.

"We are delighted to share the long awaited product line extension with a demonstration of the Fidelity 300. The Research and Development Team have been working hard to unveil the Fidelity 300 at the ACC Meeting and we are exited about this and other new products presently under development. These are very exciting times for the company and for the cardiology community. We expect to make a significant contribution to the diagnosis and treatment of cardiovascular disease," states Pam Bunes, President and Chief Executive Officer.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.